Mallinckrodt (MNK) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual General Meeting scheduled for May 15, 2025, in Dublin, Ireland, with voting open until May 14, 2025 at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 1, 2025.
Voting covers director elections, auditor re-appointment, and executive compensation.
Voting matters and shareholder proposals
Election of five directors: Paul M. Bisaro, Katina Dorton, Abbas Hussain, Sigurdur O. Olafsson, and Wesley P. Wheeler, all recommended for approval.
Advisory vote to approve re-appointment of independent auditors and authorize Audit Committee to set remuneration.
Advisory vote on executive compensation (say-on-pay).
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Board recommends all director nominees for election at the Annual General Meeting.
Latest events from Mallinckrodt
- Branded product growth and merger drive 2025 outlook, with sales guided up to $3.62B.MNK
Q2 202516 Feb 2026 - Q3 2025 net sales up 49% to $753.1M, led by Acthar Gel growth and Endo merger contributions.MNK
Q3 202513 Feb 2026 - Q2 sales up 8.3%, guidance raised, and Therakos sale to reduce net debt by 50%+.MNK
Q2 20242 Feb 2026 - Net sales rose, losses narrowed, and Therakos sale will cut net debt by over 60%.MNK
Q3 202416 Jan 2026 - Restructuring, innovation, and focused growth drive strong performance and lower debt.MNK
Jefferies London Healthcare Conference 202413 Jan 2026 - Merger forms a pharma leader with $3.6B revenue, $150M synergies, and strong 2024 results.MNK
Q4 202426 Dec 2025 - Merger forms a $6.7B global pharma leader with $150M annual synergies and NYSE listing planned.MNK
M&A Announcement26 Dec 2025 - 2025 AGM features director elections, auditor re-appointment, and say-on-pay after major restructuring.MNK
Proxy Filing2 Dec 2025 - EGM to vote on rebranding, major preferred share capital increase, and Board-recommended proposals.MNK
Proxy Filing2 Dec 2025